Literature DB >> 22563933

Drug-/radiation-induced interstitial lung disease in the United Kingdom general population: incidence, all-cause mortality and characteristics at diagnosis.

Rajeev K Amar1, Susan S Jick, Daniel Rosenberg, Toby M Maher, Christoph R Meier.   

Abstract

BACKGROUND AND
OBJECTIVE: Radiotherapy and an increasing number of substances are implicated in the pathogenesis of interstitial lung disease (ILD). While the frequency of published data on more common ILD entities such as the idiopathic interstitial pneumonias has increased in recent years, less attention has been given to relatively rarely occurring forms such as drug-/radiation-induced ILD.
METHODS: Data from the UK-based General Practice Research Database (GPRD) was used to estimate the incidence of drug-/radiation-induced ILD over a 12-year period (1997-2008). Crude incidence rates were stratified by gender, age group and calendar period, and rate ratios were adjusted using Poisson regression. All-cause mortality was modelled using Cox regression, and characteristics at diagnosis were compared with a random sample of matched, non-ILD controls using conditional logistic regression.
RESULTS: A total of 128 patients with an incident diagnosis of drug-/radiation-induced ILD were identified, and the overall incidence density during the study period was 4.1 (95% confidence interval 3.4-4.9) per million person-years. Incidence rates increased during the time period 1997-2005 and decreased thereafter. The adjusted all-cause mortality was >4 times higher in cases compared with controls.
CONCLUSIONS: This UK population-based study characterizes patients diagnosed with drug-/radiation-induced ILD and quantifies incidence and all-cause mortality during 1997-2008. No statistically significant time trend in incidence was found, despite having observed numeric increases in incidence rates during the study window. Future research using the GPRD and other data sources is required to better understand the disposition of patients diagnosed with drug-/radiation-induced ILD and to investigate potential trends incidence and mortality over time.
© 2012 The Authors. Respirology © 2012 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Year:  2012        PMID: 22563933     DOI: 10.1111/j.1440-1843.2012.02187.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  5 in total

1.  Association between anti-TNF-α therapy and interstitial lung disease.

Authors:  Lisa J Herrinton; Leslie R Harrold; Liyan Liu; Marsha A Raebel; Ananse' Taharka; Kevin L Winthrop; Daniel H Solomon; Jeffrey R Curtis; James D Lewis; Kenneth G Saag
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-01-29       Impact factor: 2.890

2.  Identifying complications of interventional procedures from UK routine healthcare databases: a systematic search for methods using clinical codes.

Authors:  Kim Keltie; Helen Cole; Mick Arber; Hannah Patrick; John Powell; Bruce Campbell; Andrew Sims
Journal:  BMC Med Res Methodol       Date:  2014-11-28       Impact factor: 4.615

Review 3.  Drug-Induced Interstitial Lung Disease: A Systematic Review.

Authors:  Sarah Skeoch; Nicholas Weatherley; Andrew J Swift; Alexander Oldroyd; Christopher Johns; Conal Hayton; Alessandro Giollo; James M Wild; John C Waterton; Maya Buch; Kim Linton; Ian N Bruce; Colm Leonard; Stephen Bianchi; Nazia Chaudhuri
Journal:  J Clin Med       Date:  2018-10-15       Impact factor: 4.241

4.  Late-onset noninfectious interstitial lung disease following autologous haematopoietic stem cell transplantation in paediatric patients.

Authors:  Yoon-Kyoung Lee; Rimm Huh; Jihyun Kim; Kangmo Ahn; Ki Woong Sung; Joongbum Cho
Journal:  Respirology       Date:  2016-04-12       Impact factor: 6.424

5.  How consistently do physicians diagnose and manage drug-induced interstitial lung disease? Two surveys of European ILD specialist physicians.

Authors:  James A Eaden; Sarah Skeoch; John C Waterton; Nazia Chaudhuri; Stephen M Bianchi
Journal:  ERJ Open Res       Date:  2020-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.